Roche and Immunogen Develop Highly Targeted Specific Cancer Drugs

Image via Wikipedia

Articles Today about Roche's partnership with ImmunoGen on TDM-1.  TDM-1 is a highly targeted cancer drug for Breast Cancer.

ImmunoGen-(IMGN)

Roche Holdings (RHHBY)

Drugs

ImmunoGen's TDM-1 Looks Strong at ESMO

BOSTON (TheStreet) -- The "armed antibody" drug TDM-1 under development by Roche and ImmunoGen(IMGN) posted a higher response rate and lower toxicity than the blockbuster breast cancer drug Herceptin, according to results from the first head-to-head study of the two drugs to be presented at a European cancer meeting Monday.


The data from the TDM-1 phase II study in front-line breast cancer patients are early and very preliminary, but also encouraging because they suggest TDM-1 may be the next-generation successor to Herceptin that Roche has been looking for.

ImmunoGen, as Roche's partner on TDM-1, stands to profit as well if the drug is approved and successful.